BioNTech Se (NASDAQ: BNTX)
BioNTech Se Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioNTech Se Company Info
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
News & Analysis
BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
Investing in Biotech Stocks in 2025
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
Investing in Vaccine Stocks
Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.
Is BioNTech Stock a Buy Now?
Or is it too late to get in on the company after its coronavirus-related success?
Why BioNTech Stock Was Sinking Today
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling.
Valuation
Earnings Transcripts
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2024.
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2024.
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
BNTX earnings call for the period ending June 30, 2024.
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
BNTX earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.